Table 1 Therapies for the different... | American Society of Hematology

Table 1

Therapies for the different phases of essential thrombocythemia

Drug	Class	Goals	Reference
ET (initial phase)
Hydroxyurea	Antimetabolite	1. Platelet reduction 2. Prevent vascular events	1
Anagrelide	Antiplatelet drug	1. Platelet reduction 2. Prevent vascular events	2
Pegylated interferon alpha-2a	Biological	1. Platelet reduction 2. Prevent vascular events 3. Prevent progression	4
INCB18424 (experimental)	JAK2 inhibitor	1. Platelet reduction 2. Prevent vascular events	10
Post-ET MF
Allogeneic stem cell transplantation	N/A	Cure	8
INCB18424(experimental)	JAK2 inhibitor	1. Decrease splenomegaly 2. Improve MF-associated symptoms	9

Drug	Class	Goals	Reference
ET (initial phase)
Hydroxyurea	Antimetabolite	1. Platelet reduction 2. Prevent vascular events	1
Anagrelide	Antiplatelet drug	1. Platelet reduction 2. Prevent vascular events	2
Pegylated interferon alpha-2a	Biological	1. Platelet reduction 2. Prevent vascular events 3. Prevent progression	4
INCB18424 (experimental)	JAK2 inhibitor	1. Platelet reduction 2. Prevent vascular events	10
Post-ET MF
Allogeneic stem cell transplantation	N/A	Cure	8
INCB18424(experimental)	JAK2 inhibitor	1. Decrease splenomegaly 2. Improve MF-associated symptoms	9

NA indicates not applicable.